Posted by Michael Wonder on 28 Oct 2020
Enhertu granted priority review in the US for the treatment of HER2 positive metastatic gastric cancer
28 October 2020 - Only HER2 directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy for previously treated patients in this setting
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental biologics license application and has also been granted priority review in the US for the treatment of patients with HER2 positive metastatic gastric or gastro-esophageal junction adenocarcinoma.
